Human/Mouse MYCL1/L-Myc Antibody

Detection of Human/Mouse MYCL1/ L‑Myc by Western Blot. Western blot shows nuclear extracts of HeLa human cervical epithelial carcinoma cell line, A549 human lung carcinoma cell line, JEG-3 human epithelial choriocarcinoma cell line, and NIH-3T3 mouse embryonic fibroblast cell line. PVDF membrane was probed with 1 µg/mL of Human/Mouse MYCL1/L-Myc Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4050) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF109). A specific band was detected for MYCL1/L-Myc at approximately 40 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 2.

MYCL1/L‑Myc in HeLa Human Cell Line. MYCL1/L-Myc was detected in immersion fixed HeLa human cervical epithelial carcinoma cell line using Goat Anti-Human/Mouse MYCL1/L-Myc Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4050) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (red, upper panel; Catalog # NL001) and counterstained with DAPI (blue, blue panel). Specific staining was localized to cytoplasm and nuclei. View our protocol for Fluorescent ICC Staining of Cells on Coverslips.

MYCL1/L‑Myc in NIH3T3 Mouse Cell Line. MYCL1/L-Myc was detected in immersion fixed NIH3T3 mouse embryonic fibroblast cell line using Goat Anti-Human/Mouse MYCL1/L-Myc Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4050) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the Northern-Lights™ 557-conjugated Anti-Goat IgG Secondary Antibody (red, upper panel; Catalog # NL001) and counterstained with DAPI (blue, lower panel). Specific staining was localized to cytoplasm and nuclei. View our protocol for Fluorescent ICC Staining of Cells on Coverslips.

Detection of Human MYCL1/L‑Myc by Western Blot Differential effects of MYC and NF-kappa B on glycolytic gene and MCT1 levels.A) Promoter region of MCT1 includes MYC and NF-kappa B binding sites. Shading reflects four independent IMR90 DNase I hypersensitivity datasets. B) IMR90 cells stably expressing ST, GFP or p53DD + hTERT (PH) and MCPyV tumor-derived early-region (PHE) with inducible expression of MYC, MYCN or MYCL were treated with dox (+) for 48 hours. Lysates were immunoblotted with the indicated antibodies. C) IMR90 PH and PHE cells inducibly expressing MYC or MYCL were transfected with RelA-specific pooled siRNA (siRelA) or non-targeting siRNA (siCtrl). After 24 hours, cells were refed with dox containing media and lysed after an additional 48 hours. Image collected and cropped by CiteAb from the following publication (https://dx.plos.org/10.1371/journal.ppat.1006020), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Human MYCL1/L‑Myc by Western Blot Differential effects of MYC and NF-kappa B on glycolytic gene and MCT1 levels.A) Promoter region of MCT1 includes MYC and NF-kappa B binding sites. Shading reflects four independent IMR90 DNase I hypersensitivity datasets. B) IMR90 cells stably expressing ST, GFP or p53DD + hTERT (PH) and MCPyV tumor-derived early-region (PHE) with inducible expression of MYC, MYCN or MYCL were treated with dox (+) for 48 hours. Lysates were immunoblotted with the indicated antibodies. C) IMR90 PH and PHE cells inducibly expressing MYC or MYCL were transfected with RelA-specific pooled siRNA (siRelA) or non-targeting siRNA (siCtrl). After 24 hours, cells were refed with dox containing media and lysed after an additional 48 hours. Image collected and cropped by CiteAb from the following publication (https://dx.plos.org/10.1371/journal.ppat.1006020), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Human MYCL1/L‑Myc by Western Blot MYC isoforms differentially regulate glycolysis gene expression and ECAR of MCC cells.A) MKL-1 and WaGa cells containing inducible vectors for MYC, MYCN or MYCL were treated with (+) or without (-) dox for 72 hours and lysates were immunoblotted with the indicated antibodies. B) ECAR (mpH/min) of MKL-1 cells inducibly expressing GFP, MYC, MYCN or MYCL after 72 hours of dox addition (minutes). Cells were treated with oligomycin (1 μM) at the indicated time point. *P < 0.05 calculated using unpaired student’s T test between MYC and MYCL samples. Image collected and cropped by CiteAb from the following publication (https://dx.plos.org/10.1371/journal.ppat.1006020), licensed under a CC-BY license. Not internally tested by R&D Systems.